In summary, KCNK15-AS1 regulated by ALKBH5-mediated m6A demethylation acted as a tumor suppressor to suppress the malignant progression of PC cells through the KCNK15–AS1/KCNK15 axis and KCNK15–AS1/PTEN/Akt axis, suggesting a promising therapeutic target for PC clinical treatment. This evidence concerns the gene PTGDR and neoplasm.